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Introduction: While paraneoplastic syndromes in patients with malignant and metastasizing tumors are common,
they are rarely associated with skin tumors showing predominantly local growth patterns. This case report relates to a
patient with giant condyloma acuminatum, also called Buschke-Löwenstein tumor, with paraneoplastic hypercalcemia,
who was successfully treated with conservative treatment.
Case presentation: The patient in question is a 48-year-old German man with a giant periscrotal tumor. Before and
during the therapy, two episodes of symptomatic hypercalcemia occurred, which were successfully treated by
bisphosphonates, intravenous fluids and diuretics. No evidence of lytic bone affection was found.
Conclusions: Paraneoplastic hypercalcemia may occur in patients who have a Buschke-Löwenstein tumor. For patients,
where surgery is not an option, established medical therapies like bisphosphonates may be useful in addition to
diuretics and infusions.
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Paraneoplastic syndromes occur commonly and are
well-known. They may appear before or during tumor
manifestation. Different types involving different tissues,
for example dermatological, neuronal or endocrino-
logical paraneoplastic syndromes, are known. An inci-
dence up to 10% of paraneoplastic hypercalcemia is
reported in patients with lung cancer. It is also com-
monly seen in aggressive cancers such as breast cancer
or multiple myeloma [1]. Paraneoplastic hypercalcemia
may appear without evidence of bone metastases [2]. It
is the most common metabolism-disorder that is in-
duced by a tumor-associated peptide-releasing hormone
[3]. Meyer-Heim et al. assumed a paraneoplastic preva-
lence in 40% of hypercalcemia [4]. Buschke-Löwenstein
tumors are rare and usually grow slowly. They are
thought to be induced by the human papilloma virus
(HPV), most commonly type 6 and 11 [5]. Usually, it is
associated with extensive local infiltration. Most authors* Correspondence: Thomas.Linnemann@gmx.de
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distribution, and reproduction in any mediumconsider it to be a verrucous carcinoma, which rarely
metastasizes [6].
Case presentation
A 48-year-old German man was admitted with a large
scrotal tumor. He had noticed a tumor mass in his right
groin 10 years prevoiusly. After a decade of steady state,
the tumor was growing rapidly in both his groins and
perineum (Figure 1). Our patient was unable to sit be-
cause of pain and tumor mass. After a histological exam-
ination, a giant condyloma acuminatum was diagnosed.
On examination, the patient was in good condition
(Karnofsky-Index: 90%, size: 189cm, weight: 75kg). Fur-
ther examination showed enlarged groin lymph nodes
on both sides and a large cauliflower-like, polycyclic
scrotal tumor reaching from pubic eminence to anal
fissure (width: 20cm, height: 18cm, depth: 25cm). His
medical history reported fatigue, but no neuromuscular
weakness, polyuria, polydipsia, nausea, vomiting or
psychotic phenomena. Arrhythmia was not observed. A
supplement of cholecalciferol was not taken. His labo-
ratory results were unremarkable except for a hyper-
calcemia (Ca2+= 3.64mmol/l). A lower than normal leveltral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Tumor before starting therapy. This is our first picture
showing the tumor mass before starting therapy.
Figure 2 Extract of pelvis computed tomography scan showing
a destructive, polycyclic growing tumor. This is a picture of a
computed tomography scan that we made to exclude bone
metastasis. It shows the tumor mass, growing from the anal region
(below in the picture) to the groin region (above). Furthermore it
shows the local destructive grow-pattern.
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(parathyroid hormone 9.9 pg/mL, LNL 15 pg/mL; phos-
hate 2.2mg/dL, LNL 2.7mg/dL) was found (Table 1). His
bone scan was normal and a computed tomography scan
of his pelvis did not show any evidence for bone affec-
tion (Figure 2). Human immunodeficiency virus (HIV)
was excluded.
A reactive hypoparathyroidism with low phosphate
caused by paraneoplastic hypercalcemia was suspected.
After a single dose of pamidronate (60mg), saline infu-
sions (3000mL/day) and diuretics (60mg furosemide/
day) serum calcium was normalized, and the patient was
discharged after six days. In follow-up examinations,
slightly elevated calcium levels without clinical signifi-
cance were detected. Due to the size of the tumor, a
combined neoadjuvant therapy which involved radio-
therapy of the tumor area up to 45Gy (gray) with a sin-
gle dose of 1.8Gy plus acitretin was conducted (50mg
daily for 43 days). The intensity-modulated radiation
therapy technique (IMRT technique) was used. During
this therapy, the patient was readmitted with fatigue and
elevated calcium levels (3.36mmol/L). His serum phos-
phate level was normal. Our patient was again treated with
a single dose of pamidronate (60mg), infusions and di-





















This table shows the serum calcium levels during the two hospital stays of our
patient. Phosphate and parathormon levels were added to show that there
was no primary hyperparathyroidism.treatment resulted in a significant regression of the tumor
mass. Pain while sitting had gone and calcium levels
remained within normal range. During follow-up exami-
nations (Figure 3) no further episodes of hypercalcemia
occured.Discussion
While paraneoplastic hypercalcemia is well-known for
many malignant diseases, it is rarely described in patients
with localized skin tumors. In a single center study with
412 patients with cutaneous squamous cell carcinoma
(SCC), Nicolae et al. reported a low PTH-independent
hypercalcemia prevalence of 1.21% [7]. Furthermore, two
cases with hypercalcemia-hyperleukocytosis paraneoplastic
syndrome in cutaneous squamous cell carcinoma were
described [8].Figure 3 Tumor after therapy.
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paraneoplastic hypercalcemia in Buschke-Löweinstein-
tumor [9]. Hernandez et al. described a patient with
Buschke-Löwenstein-tumor and elevated PTH-related
protein (PTH-rp). After surgical treatment, hypercalce-
mia was normalized and PTH-rp became undetectable.
In this patient, surgery finally resolved the problem. In
our patient however, primary surgery was not an option
due to the size and mass of the tumor. In the case of
paraneoplastic syndrome some authors suggest a three
point management plan: involving treatment of the pri-
mary tumor to eliminate the source of antigens; steroid
based-immunosuppression to avoid antigen-antibody re-
actions; and symptomatic medication with bisphospho-
nates, diuretics and infusions to lower elevated calcium
levels [10]. In this case, the use of steroids was withheld
to await the effect of radiotherapy.
Conclusions
Paraneoplastic hypercalcemia may occur in patients with
Buschke-Löwenstein tumor. For patients who are not
suitable for surgery, established medical therapies like
bisphosphonates may be useful in addition to diuretics
and infusions.
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